BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 38007409)

  • 1. Cantharidin Topical Solution 0.7%: First Approval.
    Keam SJ
    Paediatr Drugs; 2024 Jan; 26(1):95-100. PubMed ID: 38007409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Topical Cantharidin Treatment for Molluscum Contagiosum and Warts: A Systematic Review.
    Vakharia PP; Chopra R; Silverberg NB; Silverberg JI
    Am J Clin Dermatol; 2018 Dec; 19(6):791-803. PubMed ID: 30097988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cantharidin in Dermatology.
    Al-Dawsari NA; Masterpol KS
    Skinmed; 2016; 14(2):111-4. PubMed ID: 27319954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cantharidin: a comprehensive review of the clinical literature.
    Torbeck R; Pan M; DeMoll E; Levitt J
    Dermatol Online J; 2014 Jun; 20(6):. PubMed ID: 24945640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cantharidin therapy for molluscum contagiosum in children.
    Epstein E
    J Am Acad Dermatol; 2001 Oct; 45(4):638. PubMed ID: 11568766
    [No Abstract]   [Full Text] [Related]  

  • 6. Pooled Results of Two Randomized Phase III Trials Evaluating VP-102, a Drug-Device Combination Product Containing Cantharidin 0.7% (w/v) for the Treatment of Molluscum Contagiosum.
    Eichenfield LF; Siegfried E; Kwong P; McBride M; Rieger J; Glover D; Willson C; Davidson M; Burnett P; Olivadoti M
    Am J Clin Dermatol; 2021 Mar; 22(2):257-265. PubMed ID: 33599960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and Efficacy of VP-102, a Proprietary, Drug-Device Combination Product Containing Cantharidin, 0.7% (w/v), in Children and Adults With Molluscum Contagiosum: Two Phase 3 Randomized Clinical Trials.
    Eichenfield LF; McFalda W; Brabec B; Siegfried E; Kwong P; McBride M; Rieger J; Willson C; Davidson M; Burnett P
    JAMA Dermatol; 2020 Dec; 156(12):1315-1323. PubMed ID: 32965495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Case report: Molluscum contagiosum. Toxic shock syndrome following cantharidin treatment.
    Langley JM; Soder CM; Schlievert PM; Murray S
    Can Fam Physician; 2003 Jul; 49():887-9. PubMed ID: 12901485
    [No Abstract]   [Full Text] [Related]  

  • 9. Beetle juice: a guide for the use of cantharidin in the treatment of molluscum contagiosum.
    Moye V; Cathcart S; Burkhart CN; Morrell DS
    Dermatol Ther; 2013; 26(6):445-51. PubMed ID: 24552407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of topical cantharidin for the treatment of pediatric molluscum contagiosum: a prospective, randomized, double-blind, placebo-controlled pilot trial.
    Guzman AK; Schairer DO; Garelik JL; Cohen SR
    Int J Dermatol; 2018 Aug; 57(8):1001-1006. PubMed ID: 29904968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase 2 Open-Label Study to Evaluate VP-102 for the Treatment of Molluscum Contagiosum.
    Niazi S; Brabec B; Anschutz L; Willson C; Davidson M; Burnett P
    J Drugs Dermatol; 2021 Jan; 20(1):70-75. PubMed ID: 33400412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Childhood molluscum contagiosum: experience with cantharidin therapy in 300 patients.
    Silverberg NB; Sidbury R; Mancini AJ
    J Am Acad Dermatol; 2000 Sep; 43(3):503-7. PubMed ID: 10954663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Berdazimer Topical Gel, 10.3%: First Approval.
    Keam SJ
    Drugs; 2024 Mar; 84(3):363-368. PubMed ID: 38409574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparative study of topical cantharidin and intralesional PPD to treat molluscum contagiosum.
    Khattab FM; Nasr MM
    J Dermatolog Treat; 2020 Dec; 31(8):850-854. PubMed ID: 31418621
    [No Abstract]   [Full Text] [Related]  

  • 15. YCANTH
    Gupta AK; Mann A; Vincent K; Abramovits W
    Skinmed; 2023; 21(5):360-363. PubMed ID: 37945366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cantharidin topical solution (Ycanth) for molluscum contagiosum.
    Med Lett Drugs Ther; 2024 Feb; 66(1696):27-29. PubMed ID: 38412266
    [No Abstract]   [Full Text] [Related]  

  • 17. Childhood skin and soft tissue infections: new discoveries and guidelines regarding the management of bacterial soft tissue infections, molluscum contagiosum, and warts.
    Rush J; Dinulos JG
    Curr Opin Pediatr; 2016 Apr; 28(2):250-7. PubMed ID: 26900921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination topical treatment of molluscum contagiosum with cantharidin and imiquimod 5% in children: a case series of 16 patients.
    Ross GL; Orchard DC
    Australas J Dermatol; 2004 May; 45(2):100-2. PubMed ID: 15068455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topical Cantharidin in the Management of Molluscum Contagiosum: Preliminary Assessment of an Ether-free, Pharmaceutical-grade Formulation.
    Del Rosso JQ; Kircik L
    J Clin Aesthet Dermatol; 2019 Feb; 12(2):27-30. PubMed ID: 30881580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cantharidin for the treatment of molluscum contagiosum: a prospective, double-blinded, placebo-controlled trial.
    Coloe Dosal J; Stewart PW; Lin JA; Williams CS; Morrell DS
    Pediatr Dermatol; 2014; 31(4):440-9. PubMed ID: 22897595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.